Search Results - "Petzer, A.L"

Nodal Status and Tumor Location -- An Unorthodox Relationship in Breast Cancer Patients by Hammer, J, Track, C, Spiegl, K.J, Thames, H.D, Seewald, D.H, Feichtinger, J, Petzer, A.L, Heck, D, Beheshti, M, Bräutigam, E

Get full text

348 What Have We Learned From Recursive Partitioning Analyses in Breast Cancer Patients? a Single Institution Report On More Than 2000 Patients by Hammer, J, Track, C, Spiegl, K.J, Thames, H.D, Seewald, D.H, Petzer, A.L, Heck, D, Feichtinger, J, Rechberger, E, Bräutigam, E

Get full text

Breast Tumor Location and the Impact of Nodal Status on Local Recurrence (LR) and Disease Free Survival (DFS) by Hammer, J, Track, C, Spiegl, K.J, Thames, H.D, Seewald, D.H, Feichtinger, J, Petzer, A.L, Beheshti, M, Pöstlberger, S, Bräutigam, E

Get full text

Which Risk Parameters Gain in Importance after Breast Conserving Surgery (BCS), Systemic Therapy (ST) and Radiation Therapy (RT)? An Analysis from 2,162 Patients by Hammer, J, Track, C, Spiegl, K.J, Thames, H.D, Seewald, D.H, Feichtinger, J, Petzer, A.L, Langsteger, W, Pöstlberger, S, Bräutigam, E

Get full text

Persisting risk after BCT in N+ and N− patients – a single institution analysis from 1485 patients by Hammer, J, Track, C, Seewald, D.H, Feichtinger, J, Thames, H.D, Petzer, A.L, Langsteger, W, Spiegl, K.J, Postlberger, S, Brautigam, E

Get full text

283P Treatment landscape of HER2-positive metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry by Gampenrieder, S.P., Rinnerthaler, G., Tinchon, C., Petzer, A.L., Balic, M., Heibl, S., Zabernigg, A., Egle, D., Sandholzer, M., Roitner, F., Andel, J., Pichler, P., Hager, C., Hubalek, M., Knauer, M., Singer, C.F., Greil, R.

Get full text

905 ORAL Risk analysis in breast cancer patients younger than 45 years: which risk parameters gain in importance after breast conserving surgery (BCS), systemic therapy (ST) and radiation therapy (RT)? by Hammer, J, Track, C, Seewald, D.H, Feichtinger, J, Thames, H.D, Langsteger, W, Petzer, A.L, Spiegl, K, Bräutigam, E, Pöstlberger, S

Get full text

89P ctDNA as an unifiable biomarker to predict response to treatment after 2 weeks of chemotherapy at the same cut-off for metastatic GEC, PC and CRC by Kirchweger, P., Doleschal, B., Kupferthaler, A., Burghofer, J., Webersinke, G., Schwendinger, S., Ennemoser, A., Jukic, E., Petzer, A.L., Rumpold, H.

Get full text

76P Prediction of response to palliative chemotherapy by circulating tumor DNA (ctDNA) kinetics in metastatic pancreatic cancer by Kirchweger, P., Kupferthaler, A., Burghofer, J., Webersinke, G., Jukic, E., Schwendinger, S., Wundsam, H., Biebl, M., Petzer, A.L., Rumpold, H.

Get full text

Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24) by Steger, G.G., Greil, R., Lang, A., Rudas, M., Fitzal, F., Mlineritsch, B., Hartmann, B.L., Bartsch, R., Melbinger, E., Hubalek, M., Stoeger, H., Dubsky, P., Ressler, S., Petzer, A.L., Singer, C.F., Muss, C., Jakesz, R., Gampenrieder, S.P., Zielinski, C.C., Fesl, C., Gnant, M.

“…This randomized phase III trial compared pathologic complete response (pCR) rates of early breast cancer (EBC) following neoadjuvant epirubicin–docetaxel (ED)…”
Get full text

Prospective observational study to evaluate the persistence of treatment with denosumab (dmab) in patients (pts) with bone metastases (BM) from solid tumors (ST) in routine clinical practice: Final analysis by Haslbauer, F., Petzer, A.L., Safanda, M., Tomova, A., Porubska, M., Bajory, Z., Niepel, D., Jäger, C., Kalinin, D., Greil, R.

Get full text

123O Randomized phase II trial of neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in early HER2-positive breast cancer (ABCSG-52/ATHENE) by Rinnerthaler, G., Egle, D., Bartsch, R., Schmitt, C.A., Petzer, A.L., Balic, M., Petru, E., Denison, U., Singer, C.F., Bjelic-Radisic, V., Gampenrieder, S.P., Knauer, M., Posch, F., Hlauschek, D., Sölkner, L., Bago-Horvath, Z.A., Filipits, M., Gili, M., Gnant, M.I., Greil, R.

Get full text

Early Lymph Node Metastasis: Altered Microrna Expression in Colon Cancer by Rammer, M., Rumpold, H., Bösmüller, H., Marschon, R., Malli, T., Kranewitter, W., Erdel, M., Deutschbauer, S., Petzer, A.L., Webersinke, G.

Get full text

616 - Early Lymph Node Metastasis: Altered Microrna Expression in Colon Cancer by Rammer, M., Rumpold, H., Bösmüller, H., Marschon, R., Malli, T., Kranewitter, W., Erdel, M., Deutschbauer, S., Petzer, A.L., Webersinke, G.

“…Recently several studies confirmed the regulatory potential of microRNAs (miRNAs). Via incomplete complementarity, miRNAs bind to mRNA targets thereby causing…”
Get full text

262PDDOCETAXEL + TRASTUZUMAB +/- NON-PEGYLATED LIPOSOMAL DOXORUBICIN +/- BEVACIZUMAB IN THE NEOADJUVANT TREATMENT OF EARLY, HER2-POSITIVE BREAST CANCER: FIRST RESULTS OF ABCSG-32 by Steger, G.G., Greil, R., Hubalek, M., Fridrik, M.A., Singer, C., Bartsch, R., Balic, M., Dubsky, P., Egle, D., Gampenrieder, S.P., Pfeiler, G., Mayr, D., Czech, T., Rinnerthaler, G., Petzer, A.L., Sevelda, P., Lang, A., Frantal, S., Rudas, M., Gnant, M.

“…Abstract Aim: ABCSG-32 was designed to evaluate the cardiac toxicity of bevacizumab (B) and non-pegylated liposomal doxorubicin (N) when added to docetaxel +…”
Get full text

Docetaxel + Trastuzumab +/- Non-Pegylated Liposomal Doxorubicin +/- Bevacizumab in the Neoadjuvant Treatment of Early, Her2-Positive Breast Cancer: First Results of Abcsg-32 by Steger, G.G., Greil, R., Hubalek, M., Fridrik, M.A., Singer, C., Bartsch, R., Balic, M., Dubsky, P., Egle, D., Gampenrieder, S.P., Pfeiler, G., Mayr, D., Czech, T., Rinnerthaler, G., Petzer, A.L., Sevelda, P., Lang, A., Frantal, S., Rudas, M., Gnant, M.

Get full text

Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation by Clausen, J, Wolf, D, Petzer, A.L, Gunsilius, E, Schumacher, P, Kircher, B, Gastl, G, Nachbaur, D

“…To define the role of quantitative graft composition and donor killer-cell immunoglobulin-like receptor (KIR) genotype in clinical outcome following…”
Get full text

Selective Expansion of Primitive Normal Hematopoietic Cells in Cytokine-Supplemented Cultures of Purified Cells From Patients With Chronic Myeloid Leukemia by Petzer, A.L., Eaves, C.J., Barnett, M.J., Eaves, A.C.

“…We have previously reported that primitive normal hematopoietic cells detectable as long-term culture-initiating cells (Ph-LTC-IC) are present at high levels…”
Get full text

Hematopoietic stem cells by Gunsilius, E, Gastl, G, Petzer, A.L

“…The adequate production of blood cells is maintained by a set of immature hematopoietic stem cells (HSC) located in the bone marrow after birth. HSC are able…”
Get full text

Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia by PETZER, A. L, EAVES, C. J, BARNETT, M. J, EAVES, A. C

“…We have previously reported that primitive normal hematopoietic cells detectable as long-term culture-initiating cells (Ph-LTC-IC) are present at high levels…”
Get full text